Últimas noticias sobre Genelux (NASDAQ:GNLX) Bolsa

Genelux

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Genelux Corp

Keybanc analyst Paul Knight maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Overweight and raises the price target from $132 to $145.

News

Price Target

Analyst Ratings

RVTY

Keybanc Maintains Overweight on Revvity, Raises Price Target to $145

Keybanc analyst Steve Barger maintains RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) with a Overweight and raises the price target from $375 to $395.

Keybanc Maintains Overweight on RBC Bearings, Raises Price Target to $395

Unusual Machines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) has announced the signing of a binding agreement to acquire of Aloft Technologies, Inc. (<a href="https://pr.report/6pai">https://www.aloft.ai/</a>), the leading FAA-approved provider of unmanned aerial system (UAS) services to enterprise, public safety, and government customers. The acquisition is almost all in stock, valued at $14.5M.
The proposed acquisition brings together companies that share commitment to strengthening the U.S. drone industry. Aloft Technologies has long been recognized as the leader in the drone fleet and airspace management sector, powering more than 70% of all FAA-approved Low Altitude Authorization and Notification Capability (LAANC) airspace authorizations in the United States. Aloft has provided more than more than 1.6 million authorizations in total, with 400,000 authorizations provided in 2024.
Aloft has been able to leverage the data collected through millions of safe flights and airspace interactions to launch <a href="https://pr.report/6paj">Air Boss</a>, their new real-time UAS air traffic management (UTM) software. With the FAA <a href="https://pr.report/6pak">forecasting</a> more than 3 million drones in the airspace by 2028, outnumbering traditional aircraft more than 10-to-1, the coordination and integration of all aircraft is critical to national security and the national economy.
The closing of the acquisition is contingent on satisfaction of customary closing conditions by the parties including Aloft obtaining stockholder approval, the delivery by Aloft of its audited financials acceptable to Unusual Machines, the receipt of certain third party consents and the holders of no more than 10% of Aloft common stock have asserted appraisal rights.

UMAC

Unusual Machines Enters Into Definite Agreement To Acquire Drone Software Company Aloft Technologies; The Acquisition Is Almost All In Stock, Valued At $14.5M

Keybanc analyst Aleksey Yefremov maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Overweight and lowers the price target from $50 to $40.

Keybanc Maintains Overweight on Olin, Lowers Price Target to $40

Buybacks

Axis Capital Enters $200M Stock Repurchase Agreement

LICY

LI-Cycle Further Expands Commercial Footprint In EU With Additional Exclusive Recycling Partnership For Its Germany Spoke

Keybanc analyst Tim Rezvan maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $50 to $37.

Keybanc Maintains Overweight on Murphy Oil, Lowers Price Target to $37

Macro Economic Events

Global

Economics

OPEC+ Discussing Changing List Of Secondary Sources It Uses To Monitor Members' Oil Output; OPEC+ Considers Proposal To Remove U.S. Government's EIA As One Of Its Secondary Sources, Sources Say

Barclays analyst Ramsey El-Assal maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $23 to $28.

RELY

Barclays Maintains Overweight on Remitly Global, Raises Price Target to $28

Keybanc analyst Aleksey Yefremov maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and raises the price target from $121 to $128.

Keybanc Maintains Overweight on Eastman Chemical, Raises Price Target to $128

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) has no revenues. He added, &#8220;It's obviously just a very big spec. I <a href="https://www.benzinga.com/quote/SMMT">can't go there.&#8221;</a>
However, HC Wainwright &amp; Co. analyst Mitchell Kapoor, on Jan. 21, reiterated Summit Therapeutics with a Buy and maintained a $44 price target.
<h3 class="wp-block-heading">This Financial Company Is &#8216;Good&#8217;</h3>
Cramer said HSBC Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBC#NYSE">HSBC</a>) is a &#8220;good&#8221; company, but added that he would recommend Banco Santander, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) if he is going to buy one of those that's a foreign bank.
HSBC, meanwhile, on Jan.6, named Lisa McGeough as President and CEO for the United States.
<h3 class="wp-block-heading">Tech Stocks In Focus</h3>
When asked about Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>), he said, &#8220;I have read so many upgrades of Western Digital that I have to believe the stock is way too cheap.&#8221;
On the earnings front, Western Digital, on Jan. 29, reported better-than-expected second-quarter revenue results.
AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) is a &#8220;cheap&#8221; stock, and it's a &#8220;good one,&#8221; Cramer said. &#8220;That one rocks.&#8221;
AppFolio, on Jan. 30, also reported better-than-expected sales results for its fourth quarter.
The Mad Money host said he doesn't want to sell Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) down here. He added, &#8220;I know that it seems like a tough stock to own. I can't sell at 21 times earnings.&#8221;
However, Deutsche Bank analyst Brad Zelnick, on Jan. 8, downgraded Adobe from Buy to Hold and lowered the price target from $600 to $475.
Price Action:
<ul>
<li>HSBC shares fell 0.5% to settle at $52.43 on Friday.</li>
<li>Summit Therapeutics shares fell 3.9% to close at $21.50 during the session.</li>
<li>Western Digital shares fell 1% to settle at $65.13.</li>
<li>AppFolio shares dipped 7.8% to close at $233.91 on Friday.</li>
<li>Adobe shares fell 1.9% to settle at $437.45.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Markets

Media

Trading Ideas

ADBE

APPF

HSBC

SMMT

Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There'

Mangoceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRX#NASDAQ">MGRX</a>), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol&#xAE;, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation.
Dermytol&#xAE; is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or long-term damage, Dermytol&#xAE; utilizes a proprietary blend of clinically validated ingredients, including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera. The <a href="https://www.globenewswire.com/Tracker?data=GwtS7MM7faaVuXF50nCiIEqF3YZclunD-W2Oc5djnaJ-5RrV_FkWU1wk8H1HdLecpsBP6LAO4Ulu2toHmYIv0l4gUDm7ZuZbxGlieKMERNfAelXeLjdK926Iw9wNYVLcLx-cgONQPCRwcPM6sjmR-gbN1e2BzjJoBQr-BEkuBWs=">patented</a> formulation harnesses the melanin-reducing properties of canola extract, providing a safer and more stable alternative to conventional ingredients like hydroquinone and kojic acid.
The efficacy of Dermytol&#xAE; as a safe and effective skincare treatment was demonstrated in vitro, where it was tested against Kojic acid—a widely used skin lightening agent derived from fungi. At medium and high concentrations, Dermytol&#xAE; was found to be more effective at reducing melanin production while being significantly less damaging to skin cells than Kojic acid. According to the <a href="https://www.globenewswire.com/Tracker?data=jb3n_m190i60gacTYqoi8qpzZ5EC-ZzRvxQAiOQ2tZabOxrf6vfaMD71kOJmf6Hi6uCZVofXr0q9dN4KnlYDwghRMo-7SZB81FrhmRg1Tm0=">study</a>, this would make Dermytol&#xAE; a superior option for individuals seeking a clinically backed solution for hyperpigmentation and overall skin health.

Biotech

General

MGRX

Mangoceuticals Announces Exclusive Distribution Agreement With Propre Energie For Dermytol, Plant-Based Skincare Proven To Address Hyperpigmentation And Acne Scars

RSLS

ReShape Lifesciences Granted International Patent For Diabetes Neuromodulation Technology In Israel; Protection Until 2039, Terms Not Disclosed

Edible Garden AG Incorporated ("Edible Garden" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>, EDBLW)), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced the expansion of its existing partnership with Walmart. The Company is adding value size fresh-cut basil to its product assortment at Walmart locations. This strategic addition underscores Edible Garden's ongoing commitment to sustainable farming practices and its dedication to reducing environmental impact through Walmart's Project Gigaton.

EDBL

Edible Garden Announces The Expansion Of Its Existing Partnership With Walmart, Adding Value Size Fresh-Cut Basil To Its Product Assortment At Walmart Locations

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) will be reporting its fourth-quarter earnings on Monday. Wall Street expects 11 cents in EPS and $775.91 million in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=PLTR" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 393.36%% over the past year, 9.71% YTD.
Let&#8217;s look at what the charts indicate for Palantir stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com//node/43426284">Palantir Technologies Plunges Overnight On Robinhood: Trump Tariff Impact Or Investor Jitters?</a>
<h2 class="wp-block-heading">PLTR Stock Strongly Bullish Ahead Of Q4 Earnings&#8230;</h2>
PLTR stock is in a strongly bullish trend, trading above its five-day, 20-day and 50-day exponential moving averages. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03065308/Screenshot-2025-02-03-at-5.22.51-PM.png" alt="" class="wp-image-762426" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03065308/Screenshot-2025-02-03-at-5.22.51-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03065308/Screenshot-2025-02-03-at-5.22.51-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
At $81.20, the stock sits comfortably above key moving averages, reinforcing upward momentum. Notably, PLTR is well above its eight-day SMA (simple moving average) of $79.79, 20-day SMA of $74.48 and 50-day SMA of $73.06, all bullish indicators suggesting continued strength. 
The 200-day SMA at $42.02 further underscores a long-term uptrend, with the stock having nearly doubled over this period.
Momentum indicators also support the bullish case. The MACD (moving average convergence/divergence) indicator at 2.61 signals increasing upside momentum, often a precursor to further gains. However, the RSI (relative strength index) at 61.03 indicates that while the stock isn&#8217;t yet overbought, it is approaching elevated levels, suggesting some caution as PLTR stock nears resistance zones. 
PLTR stock investors should watch for potential consolidation or minor pullbacks, but the overall technical picture remains bullish.
<h2 class="wp-block-heading">&#8230;Yet Palantir Analysts See 9% Downside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/PLTR/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Palantir stock stands at a Neutral currently with a price target of $39.38. Recent analyst ratings from Wedbush, Cantor Fitzgerald and Morgan Stanley imply an 8.77% downside for PLTR stock, with an average price target of $74.
PLTR Stock Price Action: Palantir stock closed the trading day Friday at $82.49, up 1.56%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/43420511">Palantir CEO Alex Karp Sounds Alarm on China&#8217;s Deepseek – Could This Threaten Palantir&#8217;s AI Dominance?</a></li>
</ul>
Photo: Shutterstock

PLTR

Palantir Q4 Earnings Countdown: Bullish Charts Vs. Bearish Analysts

Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) released its Q4 earnings on Monday, February 3, 2025 at 07:30 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Saia beat estimated earnings by 3.0%, reporting an EPS of $2.84 versus an estimate of $2.77.
Revenue was up $37.82 million from the same period last year.
<h3>Earnings History Overview</h3>
The company missed on EPS by $0.07 in the previous quarter, leading to a 11.0% increase share price change the next day.
Here's a look at Saia's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.53</td>
<td>4</td>
<td>3.44</td>
<td>3.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.46</td>
<td>3.83</td>
<td>3.38</td>
<td>3.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>839.88M</td>
<td>826.55M</td>
<td>770.66M</td>
<td>744.99M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>842.10M</td>
<td>823.24M</td>
<td>754.77M</td>
<td>751.13M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Saia <a href="https://www.benzinga.com/quote/SAIA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

SAIA

Saia: Q4 Earnings Insights

Stran &amp; Company, Inc. ("Stran" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAG#NASDAQ">SWAG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAGW#NASDAQ">SWAGW</a>), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today reported preliminary selected unaudited results for the fourth quarter and full year ended December 31, 2024.
For the fourth quarter of 2024, revenue is expected to be approximately $27 million, reflecting a 17.8% increase compared to approximately $23 million expected to be reported for the fourth quarter of 2023 on a restated basis. For the full year 2024, revenue is projected to reach approximately $83 million, representing a 9.3% increase from $76 million in 2023. The Company expects to report that it had approximately $18 million in cash equivalents and investments and no long-term debt as of December 31, 2024.

Guidance

SWAG

SWAGW

Stran Announces Q4 2024 Revenue Of $27M, Up 17.8% From $23M In Q4 2023; FY24 Revenue Projected At $83M, A 9.3% Increase Over $76M In 2023; $18M In Cash and Investments, No Long-Term Debt As Of December 31, 2024.

TNYA

Tenaya Therapeutics Receives $8M Clinical Grant From California Institute For Regenerative Medicine; Funding will Support RIDGE-1 Clinical Trial Of TN-401 Gene Therapy

Dividends

Standard Motor Products Announces An Increase In Its Quarterly Common Stock Dividend From $0.29 Per Share To $0.31 Per Share, Payable On March 3, 2025, To Shareholders Of Record On February 14, 2025.

Barclays analyst Ramsey El-Assal maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Overweight and raises the price target from $595 to $650.

Barclays Maintains Overweight on Mastercard, Raises Price Target to $650

Genelux started at buy by Guggenheim ahead of Olvi-vec data

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

An update from Genelux Corp. ( ($GNLX) ) is now available. Genelux Corporation has released a new corporate presentation that may shape future disc...

Genelux Corp. Releases New Corporate Presentation

The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. W...

These 2 "Strong Buy" Penny Stocks Are Set to Triple (or more), Say Analysts

"Over the past quarter, we marked another important step forward in our efforts to advance the systemic delivery of Olvi-Vec and to demonstrate the...

Genelux reports Q3 EPS (19c), consensus (19c)

Genelux GAAP EPS of -$0.19 beats by $0.01

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Genelux Corp. (GNLX – Research Report), with a price tar...

Genelux Corp's Strategic Advances in Cancer Trials Position GNLX as a Promising Investment

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Genelux Corp. ( ($GNLX) ) has shared an announcement. Genelux Corporation announced the resignation of Lourie Zak as Chief Financial Officer on Jan...

Comments

Genelux

Noticias

Últimas noticias sobre Genelux (NASDAQ:GNLX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL